Ifetroban

Ifetroban
Clinical data
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 3-[2-({(1S,2R,3S)-3-[4-(Pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]hept-2-yl}methyl)phenyl]propanoic acid;
CAS Number	143443-90-7;
PubChem CID	23724921;
DrugBank	DB12321;
ChemSpider	58452;
UNII	E833KT807K;
KEGG	D04500;
ChEMBL	ChEMBL2146062;
CompTox Dashboard (EPA)	DTXSID40869931 ;
Chemical and physical data
Formula	C25H32N2O5
Molar mass	440.540 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NCCCCC)c1nc(oc1)[C@@H]4C2O[C@@H](CC2)[C@@H]4Cc3ccccc3CCC(=O)O;

Ifetroban is a potent and selective thromboxane receptor antagonist.^[1] It has been studied in animal models for the treatment of cancer metastasis,^[2] myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy,^[3] and for its effects on platelets.^[4]^[5] Clinical trials are evaluating the therapeutic safety and efficacy of oral ifetroban capsules for the treatment of cancer metastasis,^[6] cardiovascular disease,^[7] aspirin exacerbated respiratory disease,^[8]^[9]^[10] systemic sclerosis,^[11] and Duchenne muscular dystrophy.^[12]